Russi E W, Marchette B, Yerger L, Abraham W M, Ahmed T
Am Rev Respir Dis. 1983 Jun;127(6):675-9. doi: 10.1164/arrd.1983.127.6.675.
Because both degranulation of mast cells and contraction of airway smooth muscle are dependent upon the influx of calcium, a calcium blocking agent might modify allergic bronchoconstriction by at least these two mechanisms. We treated sheep allergic to Ascaris suum antigen with the calcium antagonist Verapamil prior to airway challenge with an aerosol of Ascaris suum antigen and also investigated the response without pretreatment. Aerosolized Ascaris suum antigen increased mean pulmonary resistance (RL) to 530% of baseline (n = 6). Pretreatment with intravenously administered Verapamil (150 micrograms/kg) increased mean RL to 225% of baseline but bronchoconstriction produced by subsequent antigen challenge was completely prevented. Verapamil did not modify bronchoconstriction produced by aerosols of histamine and carbachol, agents that act upon airway smooth muscle. Further, it did not reverse the increase in RL induced by an intravenous infusion of carbachol. These results suggest that verapamil, at the dosage used, did not prevent allergic bronchoconstriction by a direct action on smooth muscle and therefore was effective by inhibiting the release of mast cell mediators.
由于肥大细胞的脱颗粒和气道平滑肌的收缩均依赖于钙的内流,因此钙阻滞剂可能至少通过这两种机制来改变过敏性支气管收缩。我们在用猪蛔虫抗原气雾剂对气道进行激发之前,先用钙拮抗剂维拉帕米治疗对猪蛔虫抗原过敏的绵羊,并且也研究了未进行预处理时的反应。雾化的猪蛔虫抗原使平均肺阻力(RL)增加至基线的530%(n = 6)。静脉注射维拉帕米(150微克/千克)进行预处理使平均RL增加至基线的225%,但随后抗原激发所产生的支气管收缩被完全阻止。维拉帕米并未改变组胺气雾剂和卡巴胆碱(作用于气道平滑肌的药物)所产生的支气管收缩。此外,它并未逆转静脉输注卡巴胆碱所诱导的RL增加。这些结果表明,所用剂量的维拉帕米并非通过直接作用于平滑肌来预防过敏性支气管收缩,因此其作用机制是抑制肥大细胞介质的释放。